(Q39686779)

14 September 2017

title

The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines (English)

1 reference

14 September 2017

1 reference

1 reference

1 reference

Xiao-Ling Li

1

1 reference

14 September 2017

Shao-Qiong Yi

2

1 reference

14 September 2017

Jian-Ming Xu

3

1 reference

14 September 2017

Yang Zhang

4

1 reference

14 September 2017

Yingying-Feng

5

1 reference

14 September 2017

Wei Chen

6

1 reference

14 September 2017

San-Tai Song

7

1 reference

14 September 2017

publication date

30 June 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

10

1 reference

14 September 2017

page(s)

1038-1047

1 reference

Mechanism of altered TNF-alpha expression by macrophage and the modulatory effect of Panax notoginseng saponins in scald mice.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Preclinical versus clinical drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.483512

10.3109/07357907.2010.483512

21 January 2018

Identifiers

DOI

1 reference

release_5ewzeserd5h7xdvaqlnyk2h5qq

14 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5ewzeserd5h7xdvaqlnyk2h5qq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference